Abstract
The inbuilt 2-N-hydroxy-1-oxo-3-carboxylic acid of isoquinolone was designed as pyrophosphate mimic for hepatitis C NS5B polymerase. Various 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid derivatives 11a-p were synthesized and evaluated as HCV NS5B polymerase inhibitors. Compound 11c exhibited moderate inhibitory potency based on the inorganic pyrophosphate generation (IC50 = 9.5 μM) and based on NTP incorporation by NS5B enzyme (IC50 = 5.9 μM). Compound 11c demonstrated antiviral activity (EC50 = 15.7 μM) and good selectivity in HCV genotype 1b replicon Ava.5 cells. Compound 11c reduced the interaction of NTP to NS5B polymerase. Docking model showed that 11c situated in similar orientation to the bound uridine triphosphate in the active site of NS5B polymerase. As a result, 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid was disclosed as a novel inbuilt γ-keto-acid pharmacophore for HCV NS5B polymerase inhibitors.
Keywords: Hepatitis C virus, non-structural protein 5B (NS5B) polymerase, α, γ-diketo acid, β-N-Hydroxy-γ-keto-acid, pyrophosphate mimic, metal chelation, structure-activity relationship, active site inhibitors, lead compound, pharmacophore
Current Medicinal Chemistry
Title: 2-Hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic Acid with Inbuilt β-N-Hydroxy-γ-keto-acid Pharmacophore as HCV NS5B Polymerase Inhibitors
Volume: 19 Issue: 4
Author(s): R. R. Deore, G. S. Chen, C. -S. Chen, P. -T. Chang, M. -H. Chuang, T. -R. Chern, H. -C. Wang and J. -W. Chern
Affiliation:
Keywords: Hepatitis C virus, non-structural protein 5B (NS5B) polymerase, α, γ-diketo acid, β-N-Hydroxy-γ-keto-acid, pyrophosphate mimic, metal chelation, structure-activity relationship, active site inhibitors, lead compound, pharmacophore
Abstract: The inbuilt 2-N-hydroxy-1-oxo-3-carboxylic acid of isoquinolone was designed as pyrophosphate mimic for hepatitis C NS5B polymerase. Various 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid derivatives 11a-p were synthesized and evaluated as HCV NS5B polymerase inhibitors. Compound 11c exhibited moderate inhibitory potency based on the inorganic pyrophosphate generation (IC50 = 9.5 μM) and based on NTP incorporation by NS5B enzyme (IC50 = 5.9 μM). Compound 11c demonstrated antiviral activity (EC50 = 15.7 μM) and good selectivity in HCV genotype 1b replicon Ava.5 cells. Compound 11c reduced the interaction of NTP to NS5B polymerase. Docking model showed that 11c situated in similar orientation to the bound uridine triphosphate in the active site of NS5B polymerase. As a result, 2-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid was disclosed as a novel inbuilt γ-keto-acid pharmacophore for HCV NS5B polymerase inhibitors.
Export Options
About this article
Cite this article as:
R. Deore R., S. Chen G., -S. Chen C., -T. Chang P., -H. Chuang M., -R. Chern T., -C. Wang H. and -W. Chern J., 2-Hydroxy-1-oxo-1,2-dihydroisoquinoline-3-carboxylic Acid with Inbuilt β-N-Hydroxy-γ-keto-acid Pharmacophore as HCV NS5B Polymerase Inhibitors, Current Medicinal Chemistry 2012; 19 (4) . https://dx.doi.org/10.2174/092986712798918833
DOI https://dx.doi.org/10.2174/092986712798918833 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amelioration of Cisplatin Induced Nephrotoxicity by Standardized Methanolic Extract of Roots of Boerhaavia diffusa
The Natural Products Journal Diet Bioactive Compounds: Implications for Oxidative Stress and Inflammation in the Vascular System
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Diversity of Human SP-A, a Molecule with Innate host Defense and Surfactant-Related Functions; Characteristics, Primary Function, and Significance
Current Pharmacogenomics Molecular Determinants of Vascular Calcification: A Bench to Bedside View
Current Molecular Medicine Using Compound Similarity and Functional Domain Composition for Prediction of Drug-Target Interaction Networks
Medicinal Chemistry Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology Possible Pathways of Hepatotoxicity Caused by Chemical Agents
Current Drug Metabolism Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design Counter-regulatory ‘Renin-Angiotensin’ System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected Patients
Infectious Disorders - Drug Targets Immunoprevention of Pancreatic Cancer
Current Medicinal Chemistry Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology Rip2: A Key Molecule that Regulates both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Omega-3 Fatty Acids: Role in the Prevention and Treatment of Psychiatric Disorders
Current Psychiatry Reviews Drug Conjugated Nanomedicine as Prodrug Carrier
Nanoscience & Nanotechnology-Asia The Physiology of Learning and Memory: Role of Peptides and Stress
Current Protein & Peptide Science MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types
Current Cancer Drug Targets Osteoprotegerin Positively Regulates Hematopoietic Progenitor Cells
Current Stem Cell Research & Therapy Contribution of the Rho-kinase to Systemic Sclerosis and Behçet’s Disease
Current Pharmaceutical Design Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology